Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 459

Results For "IP"

10518 News Found

Sucralose safe to use in small doses; reveals MDRF study
News | August 07, 2024

Sucralose safe to use in small doses; reveals MDRF study

Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers


UK Relonchem receives marketing authorization for Levonorgestrel 1.5 mg Tablets
News | August 06, 2024

UK Relonchem receives marketing authorization for Levonorgestrel 1.5 mg Tablets

Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA


Narayana Hrudayalaya posts Q1 FY25 consolidated PAT higher at Rs. 201.37 Cr
News | August 06, 2024

Narayana Hrudayalaya posts Q1 FY25 consolidated PAT higher at Rs. 201.37 Cr

Narayana Hrudayalaya has reported total income of Rs. 1364.44 crores during the period ended June 30, 2024


Lupin completes  successful Phase 3 trials for Lucentis biosimilar
Biotech | August 06, 2024

Lupin completes successful Phase 3 trials for Lucentis biosimilar

The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU


Lupin receives USFDA approval for Prednisolone Acetate Ophthalmic Suspension USP
News | August 06, 2024

Lupin receives USFDA approval for Prednisolone Acetate Ophthalmic Suspension USP

Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity


OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously
News | August 06, 2024

OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously

Revolutionary technology will further boost OneSource’s scientific services offerings


Vijaya Diagnostic Centre reports Q1 FY25 consolidated PAT at Rs. 31.34 Cr
News | August 06, 2024

Vijaya Diagnostic Centre reports Q1 FY25 consolidated PAT at Rs. 31.34 Cr

Vijaya Diagnostic Centre has reported total income of Rs. 159.78 crores during the quarter ended June 30, 2024


Indraprastha Medical Corporation posts Q1 FY25 PAT at Rs. 44.77 Cr
News | August 06, 2024

Indraprastha Medical Corporation posts Q1 FY25 PAT at Rs. 44.77 Cr

Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024


Cupid post Q1 FY25 profit at Rs. 8.25 Cr
News | August 06, 2024

Cupid post Q1 FY25 profit at Rs. 8.25 Cr

Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024


SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr
News | August 06, 2024

SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr

SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024